The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma.
Kiarash SalafianChristine MazimbaLeonid VolodinIndumathy VaradarajanAsal PilehvariWen YouZiyad O KnioKaren BallenPublished in: Bone marrow transplantation (2024)
Autologous hematopoietic stem cell transplantation (ASCT) is the standard of care for eligible patients with multiple myeloma (MM) to prolong progression-free survival (PFS). While several factors affect survival following ASCT, the impact of social determinants of health such as the CDC Social Vulnerability Index (SVI) is not well documented. This single-center retrospective analysis evaluated the impact of SVI on PFS following ASCT in MM patients. 225 patients with MM who underwent ASCT participated, with 51% transplanted in the last 5 years. At 5 years post-transplant, 55 (50%) achieved PFS and 66 (60%) remained alive. Higher SVI values were significantly associated with lower odds of PFS (OR = 0.521, p < 0.01, 95% CI [0.41, 0.66]) and OS (OR = 0.592, p < 0.01, 95% CI [0.46, 0.76]) post-transplant. Greater vulnerability scores in the socioeconomic status (OR = 0.890; 95% CI: [0.82, 0.96]), household characteristics (OR = 0.912; 95% CI: [0.87, 0.95]), and racial and ethnic minority status (OR = 0.854; 95% CI: [0.81, 0.90]) themes significantly worsened the odds of PFS. These results suggest high SVI areas may need more resources to achieve optimal PFS and OS. Future studies will focus on addressing factors within the socioeconomic status, household characteristics, and racial and ethnic minority subthemes, as these have a more pronounced effect on PFS.
Keyphrases
- free survival
- healthcare
- multiple myeloma
- stem cells
- climate change
- mental health
- end stage renal disease
- public health
- bone marrow
- ejection fraction
- cell therapy
- newly diagnosed
- risk assessment
- mesenchymal stem cells
- peritoneal dialysis
- platelet rich plasma
- pain management
- health information
- chronic pain
- human health